RxDoctor Payments Data

Jane Abraham, DO

Family Medicine · Colleyville, TXNPI 1356761522

Payments from drug & device makers

$10,116in general payments, 2019–2025

Across 548 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$908
  • Lilly USA, LLC$800
  • Novo Nordisk$645
  • Boehringer Ingelheim$418
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,116100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,116 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$5,342
Medicare patients
24
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide95$110,742
JardianceEmpagliflozin51$54,577
OzempicSemaglutide37$49,297
JanuviaSitagliptin Phosphate39$34,081
EliquisApixaban38$30,914
MyrbetriqMirabegron27$29,558
TrulicityDulaglutide15$18,987
Janumet XrSitagliptin Phos/Metformin Hcl11$17,995
JanumetSitagliptin Phos/Metformin Hcl12$14,327
SymbicortBudesonide/Formoterol Fumarate18$5,458
SynthroidLevothyroxine Sodium31$3,883
Atorvastatin Calcium424$3,623
Sumatriptan Succinate14$3,504
Levothyroxine Sodium309$2,899
Omeprazole127$2,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$800$129,730110 claims
MerckJanuvia, Janumet Xr, Janumet$139$66,40462 claims
Boehringer IngelheimJardiance$418$54,57751 claims
Novo NordiskOzempic$645$49,29737 claims
PfizerEliquis$298$30,91438 claims
Astellas Pharma US IncMyrbetriq$225$29,55827 claims
AstraZenecaSymbicort$1,380$5,45818 claims
AbbVieSynthroid$1,206$3,88331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Colleyville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →